Tryptophan

Tryptophan

SCHEMBL289043

N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O.N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 1.00
KDM4E B2RXH2 3/20 1.00
MAPT P10636 3/20 1.00
LMNA P02545 2/20 1.00
TSHR P16473 2/20 1.00
BLM P54132 2/20 1.00
PMP22 Q01453 2/20 1.00
MEN1 O00255 2/20 1.00
MPO P05164 1/20 1.00
HIF1A Q16665 1/20 1.00
SMN1; SMN2 Q16637 1/20 0.70
APAF1 O14727 1/20 0.68
POLB P06746 1/20 0.68
RECQL P46063 1/20 0.68
L3MBTL1 Q9Y468 1/20 0.68
HTR2A P28223 3/20 0.68
HTR1A P08908 2/20 0.68
HTR2C P28335 2/20 0.68
SLC6A4 P31645 2/20 0.68
HTR7 P34969 2/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dl-Tryptophan SCHEMBL289042 1.00 KMT2A (1.00) KMT2AKDM4EMAPTLMNATSHR
Dl-Tryptophan SCHEMBL475349 1.00 KMT2A (1.00) KMT2AKDM4EMAPTLMNATSHR
Dl-Tryptophan SCHEMBL7327 1.00 KMT2A (1.00) KMT2AKDM4EMAPTLMNATSHR
Tryptophan SCHEMBL475350 1.00 KMT2A (1.00) KMT2AKDM4EMAPTLMNATSHR
Tryptophan SCHEMBL4732053 1.00 KMT2A (1.00) KMT2AKDM4EMAPTLMNATSHR
Tryptophan SCHEMBL23141133 1.00 KMT2A (1.00) KMT2AKDM4EMAPTLMNATSHR
Dl-Tryptophan SCHEMBL1120026 1.00 KMT2A (1.00) KMT2AKDM4EMAPTLMNATSHR
Dl-Tryptophan SCHEMBL4732052 1.00 KMT2A (1.00) KMT2AKDM4EMAPTLMNATSHR
Dl-Tryptophan SCHEMBL19161120 1.00 KMT2A (1.00) KMT2AKDM4EMAPTLMNATSHR
Tryptophan SCHEMBL30343446 1.00 KMT2A (1.00) KMT2AKDM4EMAPTLMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117924422-A Tryptophan and tryptophan cross-chain interaction beta-hairpin antibacterial peptide as well as preparation method and application thereof 东北农业大学 2024-04-26 CN claimed
WO-2024041535-A1 NANO-COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF 赣州和美药业股份有限公司 2024-02-29 WO claimed
CN-117599013-A Nanometer composition, preparation method and application thereof 赣州和美药业股份有限公司 2024-02-27 CN claimed
CN-114099713-B Molecular probe for in vivo detection of CDK4/6 kinase activity and application thereof 厦门大学附属翔安医院 2023-09-01 CN claimed
CN-114099713-A Molecular probe for in vivo detection of CDK4/6 kinase activity and application thereof 厦门大学附属翔安医院 2022-03-01 CN claimed
CN-111182913-A Methods and compositions for effective delivery through multiple biological barriers 西奈医疗中心 2020-05-19 CN claimed
CN-102076221-B The product for preparing the method for wrapped, the hot preserved aqueous drink comprising casein micelles and the peptide rich in tryptophan and thereby obtaining 帝斯曼知识产权资产管理有限公司 2017-07-04 CN claimed
US-20160177329-A1 METHOD OF INHIBITING SPROUTING IN PLANT TISSUES ACADEMIA SINICA (TW) 2016-06-23 US claimed
US-9230708-B2 Self assembly of naphthalene diimide derivatives and process thereof JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) 2016-01-05 US claimed
US-20130302587-A1 SELF ASSEMBLY OF NAPHTHALENE DIIMIDE DERIVATES AND PROCESS THEREOF JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) 2013-11-14 US claimed
EP-1589034-A2 Rationally designed antibodies ALEXION PHARMACEUTICALS, INC. (US) 2005-10-26 EP claimed
EP-1370589-A2 RATIONALLY DESIGNED ANTIBODIES ALEXION PHARMACEUTICALS, INC. (US) 2003-12-17 EP claimed
EP-1292609-A2 PEPTIDES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF BURKHOLDERIA CEPACIA HERCULES INCORPORATED (US) 2003-03-19 EP claimed
US-20030049683-A1 Immunoglobulin for use in human therapeutics and diagnostics ALEXION PHARMACEUTICAL, INC. 2003-03-13 US claimed
WO-2002046238-A2 RATIONALLY DESIGNED ANTIBODIES ALEXION PHARMACEUTICALS, INC. (US) 2002-06-13 WO claimed
US-20020051819-A1 Peptides, compositions and methods for the treatment of burkholderia cepacia HERCULES INCORPORATED 2002-05-02 US claimed
WO-2001098364-A2 PEPTIDES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF BURKHOLDERIA CEPACIA HERCULES INCORPORATED (US) 2001-12-27 WO claimed
US-6232293-B1 ADMINISTERING TRYPTOPHAN-TRYPTOPHAN, TRYPTOPHAN-TYROSINE, OR TYROSINE-TRYPTOPHAN DIPEPTIDE COUPLED TO PROTEIN OR PEPTIDE CARRIER AS ANTIINFLAMMATORY AGENT ANDERSON BYRON E (US) 2001-05-15 US claimed
US-5977076-A CARRIER COUPLED TO DIPETIDE; ANTIINFLAMMATORY AGENTS; GRAFTING TISSUE ANDERSON BYRON E (US) 1999-11-02 US claimed
WO-1998046248-A1 METHOD AND MATERIAL FOR INHIBITING COMPLEMENT ANDERSON BYRON E (US) 1998-10-22 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020051819-A1 Peptides, compositions and methods for the treatment of burkholderia cepacia NGLY1, VIP, CSTB KMT2A 4667/4885KDM4E 4776/4885MAPT 4266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.